"... A key public health goal is to develop a universal influenza vaccine that would protect against most or all seasonal strains of influenza virus and potential pandemic strains."
SCIENTISTS and clinicians from the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health) and the California Institute of Technology discussed key considerations for developing a universal influenza vaccine in a workshop that brought together U.S. and international specialists from academia, industry, and government to identify--and set goals to fill--knowledge gaps concerning influenza research. NLAJD is using the subsequent report to develop a strategic plan and research agenda aimed at the development of a universal influenza vaccine. Licensed influenza vaccines provide sub-optimal protection against seasonal influenza, must be updated regularly to match circulating influenza strains, and offer little or no protection against newly emerged pandemic influenza strains. Thus, a key public health goal is to develop a universal influenza vaccine that would protect against most or all seasonal strains of influenza virus and potential pandemic strains.
Scientists have been developing universal influenza vaccine strategies, including vaccines that target conserved areas of the influenza virus that remain relatively unchanged season to season. However, critical scientific questions remain unanswered and must be addressed to accelerate this research.
Meeting attendees noted the need for improved influenza surveillance (especially in certain regions and subpopulations), as well as a better characterization of how influenza viruses are transmitted. They also encouraged more research on immune responses to influenza vaccination and infection, including the impact of preexisting immunity on responses to future vaccinations or influenza exposures.
One way to address these questions, the report notes, would be to conduct long-term natural history studies that include people of various ages from different regions of the world. Such studies also could help define other factors that affect host immunity and delineate mediators of viral pathogenesis. Standardized human challenge models--studies in which healthy adult volunteers purposely are infected with influenza under careful medical supervision in an inpatient setting--could serve as another tool to help understand immunity to influenza and rapidly assess new vaccine candidates.
Attendees discussed limitations in current influenza diagnostics, and the report calls for improved techniques to define and measure correlates of protection against influenza infection. They also debated the pros and cons of using various animal models to test vaccine candidates, study influenza transmission, and better understand viral pathogenesis and the immune response to influenza.
The report concludes by emphasizing the need for improved coordination among various scientific disciplines to prioritize and ultimately realize shared research goals.
Jennifer Routh is a news and science writer for the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Bethesda, Md.
BY JENNIFER ROUTH
"Cream"ing the Flu
A phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a "pre-pandemic" influenza vaccine is underway at Baylor College of Medicine. Investigators are evaluating whether imiquimod cream, which commonly is used to treat genital warts and certain skin cancers, can boost the body's immune response to an H5N1 influenza vaccine.
The trial enrolled 50 healthy adults ages 18-50 years. Baylor University is one of the Vaccine and Treatment Evaluation Units (VTEUs) --a network of clinical research sites that rapidly can enroll large volunteer cohorts to evaluate experimental vaccines...